Carador Income Fund (CIFU LN) Strong primary and secondary market CLO activity | Future (FUTR LN) Delivering monetisation for investors | Horizon Discovery Group (HZD LN) New gene editing platform broadens capability; reiterate Buy | Midatech Pharma (MTPH LN) Lead candidate selected in glioma programme | Restore (RST LN) Positive start to 2017, lifting Target Price to 470p | StatPro Group (SOG LN) Trading in Q1 in line with expectations | Vectura Group (VEC LN) Positive Phase I VR942 data to be ....
22 May 2017
N+1 Singer - Morning Song 22-05-2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Morning Song 22-05-2017
Restore plc (RST:LON), 218 | Statpro Group (SOG:LON), 0 | Future plc (FUTR:LON), 0 | Biodexa Pharmaceuticals plc Sponsored ADR (BDRX:NAS), 0
- Published:
22 May 2017 -
Author:
N+1 Singer Team -
Pages:
14
Carador Income Fund (CIFU LN) Strong primary and secondary market CLO activity | Future (FUTR LN) Delivering monetisation for investors | Horizon Discovery Group (HZD LN) New gene editing platform broadens capability; reiterate Buy | Midatech Pharma (MTPH LN) Lead candidate selected in glioma programme | Restore (RST LN) Positive start to 2017, lifting Target Price to 470p | StatPro Group (SOG LN) Trading in Q1 in line with expectations | Vectura Group (VEC LN) Positive Phase I VR942 data to be ....